Antonio Cusmai

982 total citations
28 papers, 577 citations indexed

About

Antonio Cusmai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Antonio Cusmai has authored 28 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Antonio Cusmai's work include Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (6 papers) and Immunotherapy and Immune Responses (5 papers). Antonio Cusmai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (6 papers) and Immunotherapy and Immune Responses (5 papers). Antonio Cusmai collaborates with scholars based in Italy, Türkiye and Spain. Antonio Cusmai's co-authors include Franco Dammacco, Maria Antonia Frassanito, Alessandro Rizzo, Gennaro Palmiotti, Giuseppe Iodice, Gennaro Gadaleta‐Caldarola, Silvana Acquafredda, L. Rinaldi, A. Misino and Elisabetta Montagna and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Antonio Cusmai

27 papers receiving 569 citations

Peers

Antonio Cusmai

ONCOL

IMMUN

HEMAT

PRM

Valérie Méresse France

Christoph Heining Germany

Marielle Chiron France

Hong Xie United States

Monika Haemmerle Germany

Laurent Vallat France

Ian Mak United Kingdom

Douglas D. Fang China

Rita Ruijter Netherlands

Christopher Riley United States

Valérie Méresse France

Antonio Cusmai

335 ×1.1

ONCOL

314 ×1.6

117 ×0.8

IMMUN

218 ×1.7

HEMAT

103 ×0.8

PRM

Citations per year, relative to Antonio Cusmai Antonio Cusmai (= 1×) peers Valérie Méresse

Countries citing papers authored by Antonio Cusmai

Since Specialization

Citations

This map shows the geographic impact of Antonio Cusmai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Cusmai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Cusmai more than expected).

Fields of papers citing papers by Antonio Cusmai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Cusmai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Cusmai. The network helps show where Antonio Cusmai may publish in the future.

Co-authorship network of co-authors of Antonio Cusmai

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Cusmai. A scholar is included among the top collaborators of Antonio Cusmai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Cusmai. Antonio Cusmai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study. Cancers. 16(20). 3442–3442. 2 indexed citations

Pinto, Antonio, Valeria Sanna, Assunta Melaccio, et al.. (2024). Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy. Pharmaceutics. 16(9). 1146–1146. 9 indexed citations

Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. Journal of Clinical Medicine. 13(23). 7441–7441. 1 indexed citations

Rizzo, Alessandro, L. Rinaldi, Raffaella Massafra, et al.. (2024). Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. Future Oncology. 20(20). 1427–1434. 2 indexed citations

Rizzo, Alessandro, L. Rinaldi, Raffaella Massafra, et al.. (2023). 412P Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes. Annals of Oncology. 34. S356–S356. 1 indexed citations

Gadaleta‐Caldarola, Gennaro, et al.. (2023). Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. Cancer Treatment and Research Communications. 37. 100775–100775. 4 indexed citations

Carloni, Riccardo, Alessandro Rizzo, Angela Dalia Ricci, et al.. (2023). Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 10. 1445–1463. 9 indexed citations

Rizzo, Alessandro, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, & Gennaro Palmiotti. (2022). Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology. 16(4). 333–339. 72 indexed citations

Rizzo, Alessandro, Angela Dalia Ricci, Antonio Cusmai, et al.. (2022). Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology. 29(2). 551–564. 5 indexed citations

10.

Gadaleta‐Caldarola, Gennaro, Alessandro Rizzo, Vincenzo Dadduzio, et al.. (2022). Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Current Oncology. 29(10). 7925–7931. 3 indexed citations

11.

Rizzo, Alessandro, Antonio Cusmai, Silvana Acquafredda, et al.. (2022). Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers. 14(6). 1404–1404. 82 indexed citations

12.

Rizzo, Alessandro, Antonio Cusmai, Silvana Acquafredda, et al.. (2022). KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncology. 18(18). 2301–2309. 52 indexed citations

13.

Carloni, Riccardo, Alessandro Rizzo, Antonio Cusmai, et al.. (2022). Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma. Future Medicinal Chemistry. 14(20). 1455–1470. 2 indexed citations

14.

Basso, Umberto, Camillo Porta, Ugo De Giorgi, et al.. (2020). 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study. Annals of Oncology. 31. S566–S566.

15.

Orlando, Laura, Marco Colleoni, Palma Fedele, et al.. (2007). Management of advanced breast cancer. Annals of Oncology. 18. vi74–vi76. 20 indexed citations

16.

Cinieri, Saverio, Laura Orlando, Palma Fedele, et al.. (2007). Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Annals of Oncology. 18. vi63–vi65. 20 indexed citations

17.

Dammacco, Rosanna, et al.. (2003). Combined cyclosporin-A /prednisone therapy of patients with active uveitis suppresses IFN-γ production and the function of dendritic cells. Clinical & Experimental Immunology. 133(2). 233–239. 13 indexed citations

18.

Frassanito, Maria Antonia, Antonio Cusmai, Cláudia Piccoli, & Franco Dammacco. (2002). Manumycin inhibits farnesyltransferase and induces apoptosis of drug‐resistant interleukin 6‐producing myeloma cells. British Journal of Haematology. 118(1). 157–165. 29 indexed citations

19.

Frassanito, Maria Antonia, Antonio Cusmai, Giuseppe Iodice, & Franco Dammacco. (2001). Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood. 97(2). 483–489. 127 indexed citations

20.

Frassanito, Maria Antonia, Antonio Cusmai, & Franco Dammacco. (2001). Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clinical & Experimental Immunology. 125(2). 190–197. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact